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Abstract. Cranberry flavonoids (flavonols and flavan-3-ols), 
in addition to their antioxidant properties, have been shown 
to possess potential in vitro activity against several cancers. 
However, the difficulty of isolating cranberry compounds 
has largely limited anticancer research to crude fractions 
without well-defined compound composition. In this study, 
individual cranberry flavonoids were isolated to the highest 
purity achieved so far using gravity and high performance 
column chromatography and LC-MS characterization. MTS 
assay indicated differential cell viability reduction of SKOV-3 
and OVCAR-8 ovarian cancer cells treated with individual 
cranberry flavonoids. Treatment with quercetin aglycone and 
PAC DP-9, which exhibited the strongest activity, induced 
apoptosis, led to caspase-3 activation and PARP deactivation, 
and increased sensitivity to cisplatin. Furthermore, immunoflu-
orescence microscopy and western blot study revealed reduced 
expression and activation of epidermal growth factor receptor 
(EGFR) in PAC DP-9 treated SKOV-3 cells. In addition, 
quercetin aglycone and PAC DP-9 deactivated MAPK-ERK 
pathway, induced downregulation of cyclin D1, DNA-PK, 
phospho-histone H3 and upregulation of p21, and arrested cell 
cycle progression. Overall, this study demonstrates promising 
in vitro cytotoxic and anti-proliferative properties of two 
newly characterized cranberry flavonoids, quercetin aglycone 
and PAC DP-9, against ovarian cancer cells.
Introduction
Epithelial ovarian cancer (EOC) is an asymptotic lethal disease 
that is frequently diagnosed at late stages in women (1). Initial 
responsiveness to chemotherapy and surgery is often thwarted 
by inherent or acquired resistance, resulting in early recurrence 
and premature death (2). Approximately 22,000 women will 
be diagnosed with EOC this year in the US alone, and more 
than 14,000 will succumb to their disease (3). Because first-
line platinum-taxane and second-line dox-topotecan therapies 
often fail, third-line chemotherapy options are urgently needed.
American cranberry (Vaccinium macrocarpon) has 
received attention in our laboratories and elsewhere because 
of the potential for cranberry A-type proanthocyanidins 
(PACs) and flavonols to treat upper urinary tract infections and 
cancer (4-6). However, the isolation of pure PACs and flavonol 
constituents has remained an unmet challenge that frequently 
impedes broad-spectrum screening for biological activity. 
Semi-pure cranberry PACs have consistently exhibited potent 
anti-proliferative activity against various cancer cells in vitro 
(6-8). We had previously developed an iterative but efficient 
HPLC and mass spectrometry-based approach to generate 
high-purity polymeric PAC fractions from cranberries (9). 
Purified PACs have exhibited cytotoxic effects against a panel 
of gynecologic cancer and neuroblastoma cells in our labo-
ratories (9-11). PACs exerted these cytotoxic effects via cell 
cycle arrest, production of lethal levels of intracellular reactive 
oxygen species (ROS), and induction of pro-apoptotic signal 
transductions at low microgram concentrations (10,11). Further 
optimization of the purification and a detailed investigation of 
the mechanism of anti-proliferative action have been pursued 
in our laboratories since purified PACs became accessible.
In this study, we further elaborate analytical methodology 
to isolate and purify individual flavonols and PACs of cran-
berry for broad-spectrum biological activity screening studies. 
We also describe the two most active leads, PAC DP-9 and 
quercetin aglycone, in SKOV-3 and OVCAR-8 ovarian cancer 
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cells, and we characterize their anti-proliferative efficacy and 
mechanism of cell cycle arrest, induction of apoptotic activi-
ties, and inhibition of oncogenes and DNA repair machinery. 
The multifaceted anti-proliferative properties exerted by these 
two cranberry flavonoids highlight their potential for treat-
ment of ovarian cancer.
Materials and methods
Plant material. Cranberry fruits of cultivar ‘Stevens’ were 
harvested from the Philip E. Marucci Center for Blueberry and 
Cranberry Research and Extension and kept frozen at -20˚C 
before use.
Reagents and LC-MS instrumentation. All solvents were 
purchased from EMD Millipore (Billercia, MA, USA). 
Sephadex® LH-20 was obtained from GE Healthcare 
Bio-Science (Piscataway, Nj, USA), and BakerBound® Diol 
was obtained from Avantor Performance Materials (Center 
Valley, PA, USA). LC-MS spectra were obtained with a 
Dionex UltiMate® 3000 LC system (Thermal Scientific, 
Sunnyvale, CA, USA) including the UltiMate 3000 RS Pump, 
UltiMate 3000 RS Autosampler, UltiMate 3000 RS Column 
Compartment and UltiMate 3000 RS Diode Array Detector 
coupled with Applied Biosystems API 3000TM triple quad 
LC-MS/MS mass spectrometer (AB SCIEX, Framingham, 
MA, USA). Previously described HPLC methods for flavonol 
and PAC identification (12,13) were modified slightly for 
LC-MS analysis. Structure and purity of flavonols and PACs 
were determined by HPLC-PDA/Fluorescence and/or LC-MS.
Extraction and isolation of individual cranberry flavonols 
and PACs. Crude flavonoids were extracted and further sepa-
rated in a Sephadex LH-20 column as previously described 
(14). Individual cranberry flavonols were isolated using a 
semi-preparative HPLC system as described previously (14). 
Individual PACs were isolated with a regular Diol gravity 
column chromatography as previously reported (9). Eight 
flavonols were isolated and characterized as myricetin-
3-galactoside, quercetin-3-galactoside, quercetin-3-glucoside, 
quercetin-3-xylopyranoside, quercetin-3-arabinopyranosdie, 
quercetin-3-arabinofuranoside, quercetin-3-rhamnopyranoside 
and quercetin aglycone. Eleven cranberry A-type PACs from 
dimer to polymer 12 (named as PAC DP-2 to PAC DP-12) were 
isolated and characterized. Purity of all isolated cranberry flavo-
noids was > 95% (w/w) based on HPLC and LC-MS analysis.
Cell lines and cell culture. SKOV-3 and OVCAR-8 cells 
(ovarian epithelial adenocarcinoma) were purchased 
from ATCC (Manassas, VA, USA). Cells were cultured 
with Dulbecco's modified Eagle's medium (DMEM, Life 
Technologies, Carlsbad, CA, USA) supplemented with 
10% fetal bovine serum (Life Technologies), 100 µg/ml strep-
tomycin and 100 µg/ml penicillin (Life Technologies) in an 
incubator at 37˚C, 5% CO2 and 95% humidity. For all assays, 
cells were allowed to attach for 24 h prior to treatment.
Cell viability assay. Cells (5,000/well) were seeded in 96-well 
flat bottom plates (USA Scientific, Orlando, FL, USA) and 
treated with various concentrations of flavonoids for 72 h. 
Cell viability was determined by CellTiter 96® Aqueous One 
Solution assay (Promega, Madison, WI, USA) following the 
manufacturer's protocol. Experiments were performed in trip-
licate; data are expressed as mean of triplicate measurements 
(mean ± SD) in percentage of untreated cells (100%). SPSS 
Statistics 19 (IBM Corp., Armonk, NY, USA) was used to 
perform ANOVA with linear regression between cell viability 
and compound concentration, calculate IC50 value of each 
cranberry flavonoid, and conduct Student's t-tests and calculate 
p-values based on mean cell viability for each treatment.
DNA fragmentation analysis. DNA fragmentation as a hallmark 
of apoptosis was studied using the Roche In Situ Cell Death 
Detection kit (Branford, CT, USA) (TUNEL assay). SKOV-3 
and OVCAR-8 cells (2x104/well) were seeded in Lab-Tek 
8-well chamber glass slides (Nalge Nunc., Naperville, IL, 
USA) and treated with 50 µg/ml PAC DP-9, 25 µg/ml quercetin 
aglycone, or DMSO vehicle control for 12 h. Cells were fixed 
with 10% neutral buffered formalin, and stained according to 
the manufacturer's protocol. Slides were then cover-slipped 
with Vectashield mounting medium with DAPI (Vector 
Laboratories, Burlingame, CA, USA). Images were acquired 
on a Nikon E800 upright microscope (Nikon Instruments, Inc., 
Melville, NY, USA) using SPOT Advanced Software (SPOT 
Imaging Solutions, Sterling Heights, MA, USA).
Western blot analysis. Cells (3x106/dish) were seeded into 
100-mm2 tissue culture dishes and treated with individual 
cranberry flavonoids. Cells were then lysed with cell lysis 
buffer (Cell Signaling Technology, Inc., Danvers, MA, USA) 
supplemented with 5 µl/ml phenylmethylsulfonyl fluoride 
(Sigma-Aldrich, St. Louis, MO, USA). Protein concentrations 
of cell lysates were determined with Pierce BCA protein assay 
kit (Pierce Technology, Rockford, IL, USA). Gel electrophoresis 
was performed in NuPAGE Gel system (Life Technologies) 
according to the manufacturer's instructions. Separated proteins 
were transferred onto a nitrocellulose membrane, which was 
then blocked with 5% non-fat milk in PBS-Tween buffer and 
probed against various primary antibodies (cleaved caspase-3 
no. 9664, cleaved PARP no. 5625, EGFR no. 4267, phospho-
EGFR no. 3777, phospho-c-Raf no. 9427, phospho-ERK1/2 
no. 4370, phospho-p53 no. 9286, p18 INK4C no. 2896, p21 Waf1/
Cip1 no. 2947, p27 Kip1 no. 3686, CDK2 no. 2546, cyclin D1 
no. 2926, cyclin D3 no. 2936, β-actin no. 8457, β-tubulin 
no. 2128; Cell Signaling Technology). Protein bands were 
visualized using horseradish peroxidase conjugated anti-rabbit 
or anti-mouse secondary antibody (Cell Signaling Technology) 
and Pierce ECL Western Blotting Substrate, and documented by 
Bio-Rad Gel Doc system (Bio-Rad, Hercules, CA, USA).
Immunofluorescence microscopy analysis. SKOV-3 and 
OVCAR-8 cells (2x104/well) were seeded in Lab-Tek 8-well 
chamber slides and treated with individual cranberry flavonoids 
overnight for 12 h. Cells were fixed with 10% neutral buffered 
formalin, washed 3 times with PBS-Tween 0.1% and blocked 
with 5% horse serum (Vector Laboratories) in PBS-Tween for 
30 min. Blocked cells were incubated with various primary 
antibodies (EGFR no. 4267, p21 Waf1/Cip1 no. 2947, phospho-
ERK1/2 no. 4370, DNA-PK no. 4602, Cell Signaling Technology; 
and MEK no. sc-166197, phospho-histone H3 no. sc-12927, 
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cyclin D1 no. sc-246, Santa Cruz Biotechnology, Dallas, TX, 
USA) at 4˚C overnight. Probed proteins were visualized with 
DyLight 488/594 (Thermo Scientific, Waltham, MA, USA) or 
Alexa Fluor® 594 (Cell Signaling Technology) secondary anti-
bodies, and nuclei were stained with Vectorshield® mounting 
medium with DAPI (Vector Laboratories). Images were 
acquired on Olympus FSX100® (Olympus America Inc., Center 
Valley, PA, USA; for EGFR) or Nikon E800 upright (for other 
proteins) microscope system.
Co-immunoprecipitation analysis. SKOV-3 and OVCAR-8 
cells were cultured in 100 mm2 tissue culture dishes to 
80% confluency. Cells were lysed and protein concentration 
was quantified as described earlier. Lysate containing 500 µg 
protein was incubated with target antibody or control IgG anti-
body (Cell Signaling Technology) for 4 h with rotation at 4˚C. 
Protein G sepharose (75 µl) (50% slurry, GE Healthcare Life 
Sciences) was added to the lysate and incubated at 4˚C over-
night. After incubation, beads were washed with 500 µl lysis 
buffer 3 times and re-suspended in 40 µl Laemmli buffer (2X, 
Bio-Rad), vortexed, and heated to 95˚C for 5 min. Suspension 
was centrifuged to collect supernatant for western blot analysis.
Cell cycle analysis. SKOV-3 and OVCAR-8 cells (3x105/well) 
were seeded in 6-well plates and treated with a series of concen-
trations of individual cranberry flavonoids (0-100 µg/ml, 
24-48 h). After trypsinization, cells were collected and fixed 
in ice-cold 70% ethanol and stained with solution containing 
propidium iodide (Sigma-Aldrich; 0.1 mg/ml), sodium citrate 
(Sigma-Aldrich; 2 mg/ml) and Triton X-100 (Sigma-Aldrich; 
1 µl/ml). Cell counting data were acquired in an Accuri® C6 
Flow Cytometer (BD Biosciences, San jose, CA, USA) and 
analyzed with ModFit LT software (Verity Software House, 
Inc., Topsham, ME, USA).
Results
Individual cranberry flavonoids display differential cytotox-
icity against ovarian cancer cell lines. Individual cranberry 
flavonols and PACs exhibited different levels of cytotoxicity 
against SKOV-3 and OVCAR-8 cell-lines (Fig. 2). Quercetin-3-
xylopyranoside did not show cytotoxicity against SKOV-3 and 
OVCAR-8 cells, while myricetin-3-galactoside and quercetin-
3-arabinopyranoside were cytotoxic to OVCAR-8 cells (IC50, 
130 and 212 µg/ml) but non-toxic to SKOV-3 cells at treatment 
concentrations. Compared to quercetin glycosides, quercetin 
aglycone exhibited higher cytotoxicity against the two cancer 
cell lines (IC50, 83 and 61 µg/ml for SKOV-3 and OVCAR-8 
cells, respectively).
Cranberry PAC DP-3, DP-7, and DP-10 exhibited less cyto-
toxicity against both SKOV-3 and OVCAR-8 cells than other 
PACs. PAC DP-5 and DP-12 were more effective against 
SKOV-3 cells (IC50, 126 µg/ml and 162 µg/ml for DP-5 and 
DP-12, respectively) than OVCAR-8 cells. Compared to other 
cytotoxic PAC molecules, PAC DP-9 exhibited the highest 
activity against SKOV-3 cells (IC50, 82 µg/ml) and relatively 
high cytotoxicity against OVCAR-8 cells (IC50, 138 µg/ml). 
Based on these results, quercetin aglycone and PAC DP-9 
(Fig. 1) were selected as lead candidates for our studies in 
Figure 1. Structures of cranberry flavonoids quercetin aglycone and PAC DP-9. (A) HPLC chromatograph of quercetin aglycone; (B) HPLC chromatograph of 
PAC DP-9; (C) MS spectrum of quercetin aglycone (m/z=301); (D) Structures of quercetin algycone and PAC DP-9.
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Figure 2. Cytotoxicity of individual cranberry flavonols and PACs in SKOV-3 and OVCAR-8 ovarian cancer cells. Cytotoxicity was determined by MTS 
cell viability assay; cells were treated with DMSO vehicle or different concentrations of cranberry flavonoids (25-200 µg/ml) for 72 h. Experiments were 
performed in triplicate; data are expressed as mean ± SD in percent of cell viability of untreated cells (100%). M-Gal, myricetin-3-galactoside;  Q-Gal, 
quercetin-3-galactoside; Q-Glu, quercetin-3-glucoside; Q-A-P, quercetin-3-arabinopyranoside; Q-A-F, quercetin-3-arabinofuranoside; Q-Xylo, quercetin-
3-xylopyranoside; Q-Rhamno, quercetin-3-rhamnopyranoside;Q-Aglycone, quercetin aglycone.
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SKOV-3 and OVCAR-8 cells. Cytotoxicity values for indi-
vidual flavonoids and statistical analysis including p-values 
and correlation coefficients are provided in Table I.
Quercetin aglycone and PAC DP-9 induced apoptosis and 
increased cisplatin sensitivity in SKOV-3 and OVCAR-8 cells. 
To examine whether apoptosis was induced in ovarian cancer 
cells upon treatment with cranberry flavonoids, western blot 
and DNA fragmentation analysis (TUNEL assay) were carried. 
As shown in Fig. 3A, quercetin aglycone induced caspase-3 
activation in both SKOV-3 and OVCAR-8 cells, and PAC DP-9 
led to caspase-3 and cleaved-PARP expression specifically in 
SKOV-3 cells.
TUNEL assay was performed to detect apoptosis-induced 
DNA fragmentation. Quercetin aglycone and PAC DP-9 
treated cells showed apoptosis-induced DNA fragmentation, 
which was detected in both SKOV-3 and OVCAR-8 cells after 
12 h of treatment (Fig. 3B). Both western blot and DNA frag-
mentation analysis confirmed apoptosis induction in ovarian 
cancer cells exposed to these two cranberry flavonoids.
To investigate whether quercetin aglycone and PAC DP-9 
could sensitize ovarian cancer cells to cisplatin, cells were 
pretreated with subtoxic concentrations of quercetin aglycone 
or PAC DP-9 for 6 h, exposed to cisplatin overnight for 12 h, 
and cell viability was analyzed. As shown in Fig. 3C, while 
subtoxic concentrations of quercetin aglycone or PAC DP-9 
alone did not reduce SKOV-3 and OVCAR-8 cell viability, 
their pretreatment significantly reduced viability of cisplatin-
treated SKOV-3 and OVCAR-8 cells, with quercetin aglycone 
acting more strongly than PAC DP-9. Thus, quercetin aglycone 
and PAC DP-9 at low concentrations sensitize the response of 
cisplatin-resistant ovarian cancer cells to cisplatin, resulting in 
enhanced cytotoxicity.
PAC DP-9 downregulated expression and activation of 
epidermal growth factor receptor (EGFR) in SKOV-3 cells 
and induced EGFR nuclear translocation. Elevated EGFR 
expression results in poor prognosis in lung, breast and 
ovarian cancer (15). EGFR expression in quercetin aglycone 
or PAC DP-9 treated ovarian cancer cells was analyzed by 
immunoblotting and immunofluorescence microscopy. To 
eliminate the effect of serum growth factors on cellular EGFR 
regulation, ovarian cancer cells were serum-deprived for 4 h 
prior to treatment, and low concentrations (5-40 µg/ml) of 
cranberry flavonoids were applied with serum-free medium to 
avoid cell toxicity. After 12 h of treatment, quercetin aglycone 
did not affect phosphorylated-EGFR levels in either SKOV-3 
or OVCAR-8 cells, but PAC DP-9 induced a dose-dependent 
Table I. Correlation coefficient (r), p-value and IC50 value of individual cranberry PACs and flavonols against SKOV-3 and 
OVCAR-8 cells.a
 SKOV-3 OVCAR-8 ------------------------------------------------------------------------------------------------------ ---------------------------------------------------------------------------------------------------
Compound Correlation coefficient p-value IC50 (µg/ml) Correlation coefficient p-value IC50 (µg/ml)
DP-2 -0.917 0.0000263 194.8 -0.919 0.0000239 143.1
DP-3 -0.804 0.00163 210.8 -0.513 0.0882 ND
DP-4 -0.923 0.0000185 200.0 -0.936 0.00000741 164.1
DP-5 -0.983 1.15x10-8 126.3 -0.738 0.00616 209.9
DP-6 -0.929 0.0000129 201.1 -0.9 0.0000674 152.6
DP-7 -0.821 0.00106 288.7 -0.736 0.00631 211.2
DP-8 -0.944 0.00000397 137.9 -0.945 0.00000356 125.7
DP-9 -0.939 0.00000584   81.9 -0.923 0.0000189 137.8
DP-10 -0.494 0.103 ND -0.565 0.0558 ND
DP-11 -0.966 3.53x10-7 165.9 -0.931 0.0000107 146.9
DP-12 -0.824 0.000978 162.6 -0.791 0.00216 248.5
M-Gal   0.331 0.293 ND -0.78 0.00275 130.7
Q-Gal -0.833 0.000757 164.8 -0.896 0.000082 132.7
Q-Glu -0.899 0.0000684 160.6 -0.929 0.000013 160.6
Q-A-P -0.665 0.0182 410.2 -0.777 0.00293 212.7
Q-A-F -0.791 0.00217 173.5 -0.908 0.0000435 171.2
Q-Xylo   0.095 0.77 ND -0.266 0.404 ND
Q-Rhamno -0.879 0.000167 207.4 -0.945 0.00000369 163.4
Q-Aglycone -0.982 1.45x10-8   83.2 -0.966 3.48x10-7   61.1
aLinear regression was conducted for each cranberry flavonoid between cell viability and compound concentration (untransformed and logarithm-
transformed). IC50 value was calculated based on best-fit regression model (r closer to -1). ND, not determined; M-Gal, myricetin-3-galactoside; 
Q-Gal, quercetin-3-galactoside; Q-Glu, quercetin-3-glucoside; Q-A-P, quercetin-3-arabinopyranoside; Q-A-F, quercetin-3-arabinofuranoside; 
Q-Xylo, quercetin-3-xylopyranoside; Q-Rhamno, quercetin-3-rhamnopyranoside; Q-Aglycone, quercetin aglycone.
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downregulation of both phosphorylated-EGFR and total 
EGFR in SKOV-3 cells (Fig. 4A). As shown in Fig. 4B, EGFR 
was expressed predominantly at the cell membrane in the 
untreated controls, and exhibited nuclear translocation within 
3 h of treatment with PAC DP-9 in a dose-dependent manner 
such that lower concentrations (12.5-25 µg/ml) induced EGFR 
peri-nuclear localization in SKOV-3 cells, and higher concen-
trations (50-200 µg/ml) of PAC DP-9 mediated EGFR nuclear 
translocation.
Quercetin aglycone and PAC DP-9 downregulated pro-
survival MAP kinase proteins in ovarian cancer cells. We 
examined changes in MAP kinase signaling regulation exerted 
by quercetin aglycone and PAC DP-9 in ovarian cancer cells. 
Expression of MEK (Fig. 5A) and phospho-ERK1/2 (Fig. 5B) 
was downregulated after 12 h of treatment with quercetin 
aglycone or PAC DP-9, indicating inhibition of pro-survival 
MAPK-ERK signal transduction by cranberry flavonoids. 
Similarly, treatment with quercetin aglycone and PAC-9 led to 
rapid, significant downregulation of phospho-p42/22 MAPK 
and phospho-c-Raf in OVCAR-8 cells within 6 h (Fig. 6A), 
demonstrating their inhibitory effect on the activated pro-
survival MAPK pathway.
Quercetin aglycone and PAC DP-9 affected cell cycle 
progression of ovarian cancer cells. Immunofluorescence 
microscopy analysis of quercetin aglycone and PAC DP-9 
treatment revealed downregulation of cyclin D1 and upregula-
tion of p21 in SKOV-3 and OVCAR-8 cells (Fig. 5D and F). 
Phospho-histone H3 (Fig. 5C) and DNA-dependent protein 
kinase (DNA-PK, Fig. 5E), proteins often overexpressed in 
ovarian cancer cells, were also downregulated in SKOV-3 and 
OVCAR-8 cells upon treatment with cranberry flavonoids. 
Based on immunoblot study, phospho-p53 and p21 expression 
were first downregulated after 6 h of treatment with quercetin 
aglycone in OVCAR-8 cells and then exhibited sustained 
Figure 3. Induction of apoptosis (A and B) and sensitization to cisplatin (C) by quercetin aglycone and PAC DP-9 in SKOV-3 and OVCAR-8 cells. (A) Expression 
of cleaved caspase-3 and cleaved PARP after treatment with PAC DP-9 and quercetin aglycone. Ovarian cancer cells were treated with PAC DP-9 or quercetin 
aglycone (80 µg/ml) for 0-24 h. Actin or tubulin were probed as internal loading controls; (B) TUNEL assay in PAC DP-9 and quercetin aglycone (Q-A)-treated 
SKOV-3 and OVCAR-8 cells. Cells were treated with PAC DP-9 (50 µg/ml), quercetin aglycone (25 µg/ml) or DMSO vehicle for 12 h. DNA strand breaks due 
to apoptosis were detected and labelled by fluorescein-labelled nucleotides (green). (C) Cell viability of cranberry flavonoid and cisplatin-treated SKOV-3 and 
OVCAR-8 cells. Cells were pre-treated with either DMSO vehicle, PAC DP-9 (25 µg/ml), or quercetin aglycone (10 µg/ml) for 6 h in complete DMEM media, 
followed by cisplatin treatment alone or cisplatin + PAC DP-9/quercetin aglycone. Cells were incubated overnight for 12 h and analyzed via MTS for viability. 
Experiments were performed in triplicate; data are expressed as mean ± SD in percent of cell viability of untreated cells (100%).
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upregulation (Fig. 6A). Three other cell cycle regulators, 
p18, p27, and CDK2 were also upregulated within 6-24 h of 
treatment with quercetin aglycone. Independent of p53 expres-
sion, SKOV-3 cells exhibited rapid upregulation of cell cycle 
inhibitor p21 after 6 h of treatment of quercetin aglycone, 
together with upregulation of p18, p27, and CDK2 within 24 h 
of treatment. Similarly, PAC DP-9 induced upregulation of p21 
in both SKOV-3 and OVCAR-8 cells within 6-24 h-treatment 
regardless of p53 expression level. CDK2 expression was also 
upregulated in SKOV-3 and OVCAR-8 cells after 24 h of 
PAC DP-9 treatment.
Because immunofluorescence microscopy and western blot 
analysis showed inhibition of SKOV-3 cellular EGFR expres-
sion by PAC DP-9 (Fig. 4), co-immunoprecipitation (Co-IP) 
was utilized to examine potential protein-protein interactions 
involved with EGFR and cell cycle regulatory factors, including 
p18, p21, p27, CDK2, cyclin D1 and cyclin D3. While most 
of the probed proteins did not show a positive signal, CDK2 
signal was detected in both SKOV-3 and OVCAR-8 EGFR 
Co-IP samples. As shown in Fig. 6B, CDK2 was recovered 
in both positive controls and two Co-IP samples as well as 
in the OVCAR-8 negative control, indicating a false-positive 
signal in the OVCAR-8 Co-IP sample. The absence of CDK2 
signal in SKOV-3 negative control confirmed direct interaction 
between CDK2 and EGFR in SKOV-3 cells.
Both western blot and Co-IP studies indicate a direct 
effect of cranberry flavonoids on ovarian cancer cell progres-
sion. Subpopulations of propidium iodide-stained SKOV-3 
and OVCAR-8 ovarian cancer cells treated with cranberry 
flavonoids were analyzed by flow cytometry. As illustrated 
in Fig. 6C and D, quercetin aglycone or PAC DP-9 treatment 
for 24 h in SKOV-3 cells led to G2/M-phase arrest dose-
dependently. The G2/M subpopulation increased from 10.81 
to 16.52% for SKOV-3 cells treated with 50 µg/ml quercetin 
aglycone and further increased to 32.35% after treatment 
with 100 µg/ml quercetin aglycone. Similarly, 50 and 100 µg/
ml PAC DP-9 caused an increase in the SKOV-3 cell G2/M 
subpopulation to 17.69 and 29.63%, respectively. After 48 h of 
treatment in SKOV-3 cells, PAC DP-9 exhibited similar dose-
dependent G2/M-phase arrest, whereas 50 and 100 µg/ml 
quercetin aglycone led to an increase in S subpopulation from 
22.01 to 45.54 and 50.35%, respectively, with no significant 
change in G2/M subpopulation. This suggests that quercetin 
aglycone caused S/G2-phase arrest in SKOV-3 cells after 48 h 
of treatment.
Quercetin aglycone treatment for 24 and 48 h in OVCAR-8 
cells caused G1/S-phase arrest. At 50 µg/ml, quercetin aglycone 
led to retention of 75.69 and 86.12% of cells in G0/G1 phase 
after 24 and 48 h of treatment, respectively, and the subpopu-
lation of S-phase cells decreased from 38.67 to 12.61% after 
24 h and from 26.35 to 6.45% after 48 h (Fig. 6D). PAC DP-9 
showed a similar effect in OVCAR-8 cells, thus confirming 
that G1/S-phase arrest was caused by the two compounds in 
OVCAR-8 ovarian cancer cells.
Discussion
Cranberry phenolic extracts have shown in vitro anticancer 
and chemo-preventive properties in different cancer cell lines 
(5-11). Research on individual phenolic compounds of cran-
berry has been limited by the difficulty of compound isolation 
due to complex structural variations, including degree-of-
Figure 4. Effects of quercetin aglycone and PAC DP-9 on expression, activa-
tion and localization of EGFR in SKOV-3 and OVCAR-8 cells. (A) Expression 
of total and activated EGFR on cranberry flavonoid treated SKOV-3 and 
OVCAR-8 cells. Cells were serum-deprived for 4 h and then treated with 
5, 20 or 40 µg/ml quercetin aglycone or PAC DP-9 in serum-free DMEM 
medium for 12 h. Actin was probed as internal loading control. (B) Effects 
of PAC DP-9 on EGFR expression and localization in SKOV-3 cells. Cells 
were treated with different concentrations (12.5-200 µg/ml) of PAC DP-9 for 
3 h before fluorescent microscopic analysis. EGFR was visualized by Alexa 
Fluor 594 secondary antibody (red), and nuclei were stained with DAPI.
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polymerization, linkage type, position of the double linkage 
between constituent units, and attachment with sugar moieties 
(9,12). Serial application of Dionex UltiMate® 3000 LC 
system consisting of UltiMate 3000 RS Pump, UltiMate 3000 
RS Autosampler, UltiMate 3000 RS Column Compartment, 
and UltiMate 3000 RS Diode Array Detector coupled with 
Applied Biosystems API 3000 triple quad LC-MS/MS mass 
spectrometer has allowed the reproducible isolation and char-
acterization of individual PACs with up to the 10th degree of 
polymerization in >95% purity in our laboratories. So far, we 
have successfully isolated 19 high-purity individual cranberry 
flavonoids, characterized their structures by LC-APCI-MS, 
and used them as primary materials to determine bioactivity.
SKOV-3 and OVCAR-8 ovarian cell lines, which possess 
several key oncogenic hallmarks such as p53 mutation, EGFR 
overexpression, and cisplatin resistance (16-18), were employed 
as an in vitro cell culture model to determine the mechanism 
of action of cranberry flavonoids. Individual PACs DP-2 to 
Figure 5. Effect of quercetin aglycone and PAC DP-9 (12-h treatment) on cellular expression of MEK (A), phospho-ERK1/2 (B), phospho-histone H3 (C), 
cyclin D1 (D), DNA-PK (E) and p21 (F) in SKOV-3 and OVCAR-8 cells. Cells were treated with either DMSO vehicle, PAC DP-9 (80 µg/ml), or quercetin 
aglycone (80 µg/ml) for 12 h and stained for target proteins. MEK, cyclin D1 and p21 were probed by DyLight 488 secondary antibody (green); phospho-
ERK1/2, phospho-histone H3 and DNA-PK were probed by DyLight 594 secondary antibody (red).
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DP-4 failed to show strong cytotoxicity against SKOV-3 cells, 
and high molecular weight PAC polymers generally exhibited 
stronger cytotoxicity similar to what we showed earlier (9). 
Quercetin aglycone emerged as the most cytotoxic of the tested 
cranberry flavonols. Shen et al showed that quercetin aglycone 
exhibited significantly higher cytotoxicity against human 
promyelocytic leukemia cells HL-60 compared to its rutinose 
and rhamnose glycosides (19). Murota et al also reported that 
quercetin aglycone was much more efficiently absorbed by 
Caco-2 colorectal adenocarcinoma cells than its glycosides 
(20). Both quercetin aglycone and PAC DP-9 induced ovarian 
cancer cell death through apoptotic events, and subtoxic 
concentrations of the two compounds significantly increased 
the efficacy of cisplatin against ovarian cancer cells. Because 
developed resistance to platinum-based drugs is one of the 
major causes of mortality in ovarian cancer (2), the observa-
tion that cranberry flavonoids can sensitize drug-resistant 
ovarian cancer cells to cisplatin provides an opportunity to 
improve the efficacy of platinum chemotherapies and reduce 
side effects associated with cisplatin.
EGFR, a receptor tyrosine kinase, is involved in many 
signaling pathways that modulate cell survival, proliferation 
and apoptosis. Aberrant activation of EGFR has been shown 
to play a critical role in cancer cell survival and develop-
Figure 6. Effect of PAC DP-9 and quercetin aglycone on cell cycle regulation in SKOV-3 and OVCAR-8 cells. (A) Western blot analysis of ERK-MAPK 
signal components and cell cycle regulatory factors in SKOV-3 and OVCAR-8 cells after treatment with quercetin aglycone or PAC DP-9 (80 µg/ml) for 
0-24 h. Tubulin was probed as an internal loading control; (B) EGFR co-immunoprecipitation on SKOV-3 and OVCAR-8 cell lysates. 1, SKOV-3 untreated 
input control; 2, OVCAR-8 untreated input control; 3, SKOV-3 EGFR-co-immunoprecipitation; 4, OVCAR-8 EGFR-co-immunoprecipitation; 5, SKOV-3 
IgG-co-immunoprecipitation control; 6, OVCAR-8 IgG-co-immunoprecipitation control. (C and D) Determination of cell cycle progression by FACS analysis 
in SKOV-3 and OVCAR-8 cells treated with 50 or 100 µg/ml quercetin aglycone or PAC DP-9 for 24-48 h. Data are presented as relative fluorescence intensity 
of G0/G1, S and G2/M phase subpopulations in 2-D charts (C) or tables (D).
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ment (18,21). B-type PACs isolated from grape seeds have 
been shown to target and downregulate EGFR expression in 
human head and neck squamous cell carcinoma (HNSCC) 
cells and inhibited their invasiveness (22). Our study showed 
that treatment with A-type PAC DP-9 decreased expression 
and activation and induced nuclear translocation of EGFR in 
SKOV-3 cells dose-dependently. Association of EGFR with 
DNA-PK, which is involved in DNA repair, has been previ-
ously reported (23,24), and its nuclear translocation has been 
confirmed to modulate DNA repair caused by cisplatin or 
radiation in mouse fibroblast cell lines (25). Although EGFR 
nuclear translocation can be expected to activate DNA-PK as a 
counter measure to DNA damage due to quercetin and PAC-9 
treatment, immunofluorescence microscopy analysis revealed 
downregulation of DNA-PK in ovarian cancer cells exposed 
to quercetin aglycone or PAC DP-9. The DNA-PK-mediated 
DNA repair that is induced by exposure to cisplatin in cancer 
cells is believed to be an important factor in reducing the 
efficacy of platinum-based chemotherapy (26,27). Therefore, 
the inhibition of DNA-PK expression in quercetin aglycone or 
PAC DP-9-treated ovarian cancer cells may partially account 
for the increased efficacy of cisplatin in ovarian cancer cells 
following quercetin aglycone or PAC DP-9 pre-treatment.
EGFR also regulates the extracellular signal-regulated 
kinase ERK-MAPK pathway to maintain normal cell growth, 
proliferation and differentiation (28). Aberrant activation of the 
EGFR-Ras-Raf-MEK-ERK cascade is believed to contribute 
to cancer development and progression (29). Both quercetin 
aglycone and PAC DP-9 downregulated activated Raf, ERK1/2 
and MEK in OVCAR-8 cells, suggesting the ERK-MAPK 
pathway may be one of the anti-proliferative mechanisms. The 
Raf-MEK-ERK pathway is also known to control cell cycle 
progression through induction of key cell cycle regulatory 
factors such as cyclins, cyclin-dependent kinases (CDKs), and 
p21 (30). Phosphorylation of histone H3, which is believed to 
play an important role in cell division and oncogene induction, 
was shown to be stimulated by Ras-MAPK signaling pathway 
(31,32). In our study, we report different levels of upregulation 
of CDK inhibitors p18, p27, and most significantly, p21 after 
treatment with quercetin aglycone or PAC DP-9, as well as 
downregulation of cyclin D1 and phospho-histone H3, indi-
cating their effects on cell cycle regulation. Expression of p21 
can be induced by either p53-dependent or independent path-
ways (33,34). In SKOV-3 cells, where the p53 gene is mutated 
and loses its expression, PAC DP-9 induced p21 upregulation 
inversely correlated with the expression of ERK1/2, suggesting 
that PAC DP-9 modulated a p53-independent ERK pathway 
that mediates p21 regulation similar to a published mechanism 
in rhabdosarcoma cells (34).
Upregulation of CDK inhibitors and downregulation of 
cyclin D1 and phospho-histone H3 induced by the two cran-
berry flavonoids reflected the ability of quercetin aglycone and 
PAC DP-9 to cause cell cycle arrest in SKOV-3 and OVCAR-8 
cells. At concentrations lower than IC50, both quercetin agly-
cone and PAC DP-9 induced G1/S phase cell cycle arrest in 
OVCAR-8 cells, consistent with the upregulation of cellular 
p21 that has been shown to inhibit CDK regulation in G1/S 
phase progression (35). On the other hand, SKOV-3 cells 
showed cell cycle arrest at G2/M phase within 24 h of treat-
ment with quercetin aglycone or PAC DP-9, similar as shown 
previously (10). Interestingly, CDK2, which is inhibited by 
p21 and facilitates G1/S phase transition (35), was upregulated 
after treatment with quercetin aglycone or PAC DP-9 in both 
SKOV-3 and OVCAR-8 cells. We confirmed direct protein-
protein interaction between EGFR and CDK2 in SKOV-3 cells 
through Co-IP, suggesting that CDK-2 overexpression could 
be induced by nuclearly localized EGFR to facilitate DNA 
repair and synthesis after exposure to quercetin aglycone or 
PAC DP-9. These observations suggest that cell division of the 
two ovarian cancer cell lines was regulated through different 
mechanisms by cranberry flavonoids. Targeting cell cycle 
checkpoints has been proposed as a promising approach to 
cancer treatment (36).
In conclusion, our study suggests that certain cranberry 
flavonols and PACs possess cytotoxic properties against 
ovarian cancer cells. The integration of quercetin and/or 
PAC DP-9 in ovarian cancer chemotherapy may provide 
for improved outcomes. Quercetin aglycone and PAC DP-9 
induced cellular apoptotic events including cell cycle arrest 
and suppression of DNA repair pathways that highlight their 
potential as dietarily available therapeutic agents.
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